Clinical Trials on Immunisation

Total 206 results

Sanofi Pasteur, a Sanofi Company

Completed

Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)

Meningococcal Immunisation (Healthy Volunteers)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to Two Meningococcal Reference Vaccines in European Toddlers

Meningococcal Immunisation (Healthy Volunteers)

Denmark, Finland, Germany
Johns Hopkins University
Merck Sharp & Dohme LLC

Completed

HPV Vaccination Study in Postpartum Women (PPV)

HPV | Human Papilloma Virus | Immunization

United States
Sanofi

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age

Meningococcal Immunisation (Healthy Volunteers)

Japan
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Respiratory Syncytial Virus Candidate Encapsulated in a Lipid Nanoparticle Based Formulation in Adults Aged 18 to 50 Years and 60 Years and Older

Respiratory Syncytial Virus Immunization

United States, Australia, Puerto Rico
Mitsubishi Tanabe Pharma Corporation
The Research Foundation for Microbial Diseases of Osaka University

Completed

Safety and Efficacy of BK1310 Intramuscular Injection in Healthy Infants

Immunization

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Imovax® Rabies and VERORAB® Immunogenicity and Safety After One Week 2-sites Intradermal or 1-site Intramuscular Pre-Exposure Prophylaxis Regimens, Followed by a Simulated Post-Exposure Prophylaxis Regimen at One Year (VAJ00001)

Healthy Volunteers (Rabies Immunization)

Philippines
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)

Ebola Disease | Immunisation

United States
University of Colorado, Denver
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Adapting Motivational Interviewing for Maternal Immunizations (MI4MI) (MI4MI)

Maternal Immunization

United States
Mitsubishi Tanabe Pharma Corporation
The Research Foundation for Microbial Diseases of Osaka University

Completed

Phase 3 Study of BK1310 in Healthy Infants

Immunization; Infection

Japan
Statens Serum Institut

Completed

Safety and Immunogenicity of a New Serum-free DTaP-IPVvero Combination Vaccine

Active Immunization

Poland
National Institute of Allergy and Infectious Diseases...

Completed

Flublok or Fluzone With Advax-CpG55.2 or AF03

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Development of Childhood Anti-Influenza Immunity

Influenza | Influenza Immunisation

United States
Centers for Disease Control and Prevention, China

Completed

Persistence of Immune Response After Vaccination With Influenza Vaccine

Influenza, Human | Immunisation Reaction

China
Pfizer

Completed

Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

Premature Birth | Safety | Immunization | 13-valent Pneumococcal Vaccine

Spain, Poland
National Institute of Allergy and Infectious Diseases...

Terminated

Evaluation of Human Immune Responses to Influenza Virus Vaccination in Healthy Volunteers

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Terminated

Analysis of Bone Marrow and Blood B Cell Immune Responses to Influenza Vaccination

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

H3N2 M2SR in Pediatric Population

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Age and Response to Flu Vaccines

Influenza | Influenza Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Two Doses of Multimeric-001 (M-001) Followed by Influenza Vaccine

Influenza | Influenza Immunisation

United States
Central Hospital, Nancy, France

Unknown

Diphtheria, Tetanus, Poliomyelitis -Pertussis-Hib Immunisation in Preterm-born Neonates (VacciPrema)

Hib Immunisation in Very Preterm-born Infants | Pertussis Immunisation in Very Preterm-born Infants

France
National Institute of Allergy and Infectious Diseases...

Completed

Safety Study of Hepatitis E Vaccine (HEV239)

Hepatitis E | Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects (FBP00004)

Healthy Volunteers | Influenza Immunisation

United States
Cancer Institute and Hospital, Chinese Academy...
Beijing Chaoyang District Centre for Disease Control and Prevention; Neimenggu...

Unknown

The Phase IVa of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17)

Safety of Inactivated EV71 Vaccine | Immunization of Inactivated EV71 Vaccine

China
National Institute of Allergy and Infectious Diseases...

Terminated

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

Gastroenteritis Escherichia Coli | Immunisation

Bangladesh
Centers for Disease Control and Prevention, China
Beijing Tiantan Biological Products Co., Ltd.

Completed

Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine

Measles | Rubella | Mumps | Adverse Event Following Immunisation

China
Alliance for International Medical Action
Institut National de la Santé Et de la Recherche Médicale, France; Programme... and other collaborators

Not yet recruiting

Increasing Measles Vaccination Coverage Through Supplementation With an SQ-LNS Incentive in Children Aged 6-23 Months

Nutrition | Vaccination | Immunization Coverage

Nigeria
National Institute of Allergy and Infectious Diseases...

Completed

2013/2017 H7N9 Prime-Boost Interval

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

2017 A/H7N9 IIV Revaccination

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4

Influenza | Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 With or Without Topical Aldara in Healthy Adults

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Phase 2 Shigella Vaccine and Challenge

Immunisation | Shigella Infection

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly

Influenza Immunisation | Avian Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine

Avian Influenza | Immunisation

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
Sanofi Pasteur, a Sanofi Company

Completed

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.

Influenza Immunization

United States, Denmark, Poland, Spain, Czechia
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Trial to Reduce Alloimmunization to Platelets (TRAP)

Hematologic Diseases | Blood Transfusion | Leukemia, Myelocytic, Acute | Immunization | Blood Platelets
Synermore Biologics (Suzhou) Co., Ltd.

Completed

A Bridging Study of the SYN023 on Healthy Adult Subjects

Vaccine Reaction | Rabies Human | Immunisation Reaction | Zoonotic Disease | Communicable Disease Transmission

China
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Monovalent mRNA Vaccine Encoding Influenza Hemagglutinin in Adult Participants 18 Years of Age and Older

Influenza | Influenza Immunization

United States
Institut Hospitalo-Universitaire Méditerranée Infection
Assistance Publique Hopitaux De Marseille; Institut Paoli-Calmettes; Hôpital... and other collaborators

Unknown

Immune Cells Phenotypes During COVID-19 (IMMUNO-COVID)

Endothelial Dysfunction | Sars-CoV2 | Immunization; Infection | Innate Immunity | Alveolar Lung Disease

France
SK Chemicals Co., Ltd.

Completed

Safety Study of NBP608 in Healthy Adult Volunteers

Immunization; Infection | Varicella Zoster

Korea, Republic of
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

Pertussis | Pertussis Immunisation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

Immunisation | Hantavirus Pulmonary Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States

Clinical Trials on Immunisation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lithuania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations